Telisotuzumab vedotin Drug Asset Due Diligence Report 2026

This Telisotuzumab vedotin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Telisotuzumab vedotin can convert its Antibody drug conjugate (ADC) profile and Tubulin x c-Met biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Telisotuzumab vedotin (query alias: Telisotuzumab vedotin)
Modality / target	Antibody drug conjugate (ADC); Tubulin x c-Met; Tubulin inhibitors, c-Met inhibitors
Highest global status	Approved
Originator	AbbVie, Inc.
Active developers	AbbVie, Inc.

The MCP disease footprint includes c-Met positive non-squamous non-small cell lung cancer, Non-squamous non-small cell lung cancer, EGFR-mutated non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06093503	Phase 3	Withdrawn	Not disclosed	PFS in the Population of Participants with no Central Nervous System (CNS) Metastases at Baseline
NCT06568939	Phase 2	Recruiting	150	Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
NCT07323641	Phase 2	Recruiting	60	Objective response rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2; n=9; evaluation: not stated. Reported fields: Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR) = 33.3 percentage of participants (95% Confidence Interval, 7.5 - 70.1); -; -

1951P - Companion diagnostic assay for c-Met protein overexpression (OE) to identify patients (pts) who may benefit from telisotuzumab vedotin (Teliso-V)

Phase 2; n=168; evaluation: Positive. Reported fields: ORR = 31.3 % ( 18.7 - 46.3); ORR = 28.3 % ( 17.5 - 41.4); ORR = 30.9 % ( 21.9 - 41.1)

Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in cMet ProteinOverexpressing NSCLC: LUMINOSITY Study

Phase 2; n=168; evaluation: Positive. Reported fields: ORR = 21.6 % ; ORR = 71.4 % ; ORR = 40.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Telisotuzumab vedotin addresses c-Met positive non-squamous non-small cell lung cancer, Non-squamous non-small cell lung cancer, EGFR-mutated non-small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-02-09	AbbVie collaborates with Pierre Fabre to develop Teliso-V for cancer treatment.	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

CLDN18.2 assay, cutoff, and intratumoral heterogeneity
Payload-related toxicity and dose intensity
Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO